Abstract
The FDA has approved the fixed-dose combination of tezacaftor and ivacaftor (Symdeko - Vertex) for oral treatment of cystic fibrosis (CF) in patients ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
